RECEIVED CENTRAL FAX CENTER AUG 0 5 2009

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (Withdrawn) A chimeric molecule comprising a polypeptide having telomerase catalytic activity fused to a telomere binding polypeptide.
- 2. (Withdrawn) The molecule according to claim 1 wherein said polypeptide having telomerase catalytic activity comprises the catalytic protein subunit of telomerase reverse transcriptase, or functional portion or variant thereof.
- 3. (Withdrawn) The molecule according to claim 2 wherein said telomerase reverse transcriptase is a mammalian telomerase reverse transcriptase, or functional portion or variant thereof.
- 4. (Withdrawn) The molecule according to claim 1 wherein said telomere binding polypeptide is selected from the group consisting of Pot1, TRF1, TRF2, PinX1, Rap1, Tin2, Tankyrase, TANK2 and Ku70/80, and functional portions and variants thereof.
- 5. (Withdrawn) The molecule according to claim 4 wherein said telomere binding polypeptide is human Pot1 (hPot1), or functional portion or variant thereof.

- (Withdrawn) The molecule according to claim 1 wherein said telomere binding 6. polypeptide is present in said molecule N-terminal to said polypeptide having telomerase catalytic activity.
- 7. (Withdrawn) The molecule according to claim 1 wherein said telomere binding polypeptide is directly linked to said polypeptide having telomerase catalytic activity.
- 8. (Currently Amended) A An isolated nucleic acid sequence encoding the molecule according to claim 1 a chimeric molecule comprising a polypeptide having telomerase catalytic activity fused to a telomere binding polypeptide, wherein said polypeptide having telomerase catalytic activity comprises a catalytic subunit of a mammalian telomerase reverse transcriptase.
- 9. (Currently Amended) The nucleic acid sequence according to claim 8 wherein said nucleic acid sequence encodes a molecule comprising the protein encoded by the nucleotide sequence set forth in SEQ ID NO:1, or functional portion or variant thereof.
- 10. (Currently Amended) The An isolated nucleic acid sequence encoding a chimeric molecule comprising a polypeptide having telomerase catalytic activity fused to a telomere binding polypeptide according to claim 8 wherein said nucleic acid sequence comprises the nucleotide sequence set forth in SEQ ID NO:1.
- 11. (Original) An expression construct comprising said nucleic acid sequence according to claim 8 operably linked to a promoter.

- August 5, 2009
 - (Original) A vector comprising the nucleic acid sequence according to claim 8. 12.
 - 13. (Original) The vector according to claim 12 wherein said vector is a viral vector.
- 14. (Original) The vector according to claim 13 wherein said viral vector is a retroviral vector, adeno-associated viral vector, lentiviral vector or adenoviral vector.
- 15. (Original) A liposome comprising the nucleic acid sequence according to claim 8.
- 16. (Original) A composition comprising the nucleic acid sequence according to claim 8 encapsulated in a polymer.
- 17. (Original) An isolated cell comprising the nucleic acid sequence according to claim 8.
- 18. (Original) The cell according to claim 17 wherein said cell is a stem or progenitor cell.
- 19. (Original) The cell according to claim 17 wherein said cell is an epithelial cell or a fibroblast.
- 20. (Original) The cell according to claim 17 wherein said cell is a muscle cell, nervous system cell, or keratinocyte.

- 21. (Original) The cell according to claim 17 wherein said cell is a human cell.
- 22. (Original) The cell according to claim 17 wherein said cell is immortal.
- 23. (Original) A method of producing a protein comprising culturing said cell according to claim 17 under conditions such that said nucleic acid sequence is expressed and said molecule is thereby produced.
- 24. (Withdrawn) A method of elongating telomere length comprising introducing into a cell the nucleic acid sequence according to claim 8 under conditions such that said nucleic acid sequence is expressed and said molecule is thereby produced and said elongation is effected.
- 25. (New) The nucleic acid according to claim 8 wherein said telomere binding polypeptide is selected from the group consisting of Pot1, TRF1, TRF2, PinX1, Rap1, Tin2, Tankyrase, TANK2 and Ku70/80.
- (New) The nucleic acid according to claim 25 wherein said telomere binding 2б. polypeptide is hPot1.
- 27. (New) The nucleic acid according to claim 25 wherein said telomere binding polypeptide is present in said molecule N-terminal to said polypeptide having telomerase catalytic activity.

- 28. (New) The nucleic acid according to claim 25 wherein said telomere binding polypeptide is directly linked to said polypeptide having telomerase catalytic activity.
- 29. (New) An expression construct comprising said nucleic acid sequence according to claim 25 operably linked to a promoter.
 - 30. (New) A vector comprising the nucleic acid sequence according to claim 25.
 - 31. (New) The vector according to claim 30 wherein said vector is a viral vector.
- 32. (New) The vector according to claim 31 wherein said viral vector is a retroviral vector, adeno-associated viral vector, lentiviral vector or adenoviral vector.
 - 33. (New) A liposome comprising the nucleic acid sequence according to claim 25.
- 34. (New) A composition comprising the nucleic acid sequence according to claim 25 encapsulated in a polymer.
- 35. (New) An isolated cell comprising the nucleic acid sequence according to claim 25.
- 36. (New) The cell according to claim 35 wherein said cell is a stem or progenitor cell.

- 37. (New) The cell according to claim 35 wherein said cell is an epithelial cell or a fibroblast.
- 38. (New) The cell according to claim 35 wherein said cell is a muscle cell, nervous system cell, or keratinocyte.
 - 39. (New) The cell according to claim 35 wherein said cell is a human cell.
 - 40. (New) The cell according to claim 35 wherein said cell is immortal.
- 41. (New) A method of producing a protein comprising culturing said cell according to claim 35 under conditions such that said nucleic acid sequence is expressed and said molecule is thereby produced.